MedTrace Logo

Avastin for PDR (Proliferative Diabetic Retinopathy)

NCT01270542 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).

Conditions

Interventions

DRUG

Avastin (bevacizumab)

single 0.05 mL intravitreal injection of bevacizumab 1.25 mg

OTHER

Sham injection

Subject's eyes will be anesthetized but no injection will be performed.

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Dean Eliott, MD · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270542 on ClinicalTrials.gov